Correction, November 4, 2026: An earlier version of this article described the pilot’s 75 percent remission as participants no longer meeting PTSD criteria and called PIVOT the VA’s first sponsored efficacy study of psilocybin. The paper defines remission as a CAPS-5 score of 20 or lower with at least a 50 percent reduction, reports that symptoms improved during preparatory therapy before dosing, and enrolled 13 participants, 12 of whom were treated. The “first” claim could not be confirmed. The passages have been revised.
The Department of Veterans Affairs announced the launch of PIVOT, Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression. It’s a multi-site randomized controlled trial comparing two psilocybin dosage levels in veterans with treatment-resistant major depressive disorder, with or without concurrent PTSD. It is the VA’s own sponsored efficacy trial, run through its Office of Research and Development, not a study VA participates in as a site for someone else’s protocol. That distinction matters. It also arrives alongside a second, closely related data point this desk has independently verified: an open-label pilot trial in veterans with severe, treatment-resistant PTSD, run through Ohio State University’s Center for Psychedelic Drug Research and Education and published just days before PIVOT’s launch. That trial reported no serious adverse events and a 75 percent remission rate at one month. Read together, they describe an institution moving from cautious research participation to sponsoring its own efficacy trials, alongside an early result that the study’s own lead author called striking.
What PIVOT actually is
PIVOT is registered on ClinicalTrials.gov as a multi-site randomized controlled trial, sponsored directly by the VA Office of Research and Development, comparing outcomes between two psilocybin dosage levels in veterans diagnosed with treatment-resistant major depressive disorder. The trial assesses depression severity before and after treatment, tolerability of side effects, and patient-reported outcomes. VA Secretary Doug Collins framed the launch plainly: “Far too many Veterans are living with mental health conditions that don’t respond to available treatments… VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform.” The trial is a long-horizon commitment, with primary completion not estimated until December 2030 and full completion in mid-2031, a multi-year efficacy program rather than a short pilot.
The result it launches alongside
Separately, and not run by the VA itself, researchers at Ohio State’s Center for Psychedelic Drug Research and Education published an open-label pilot trial in Communications Medicine examining psilocybin-assisted therapy in twelve veterans with severe, treatment-resistant PTSD. Participants received two psilocybin doses, 15 milligrams followed by 25 milligrams two to three weeks later, alongside roughly eight hours of therapy before and after each session. The safety profile was clean: no serious adverse events, and no increase in suicidal thinking or behavior, a meaningful finding in a population selected specifically for severity and treatment resistance. The efficacy signal was strong for a pilot: nine of the 12 participants (75 percent) met the paper’s criteria for treatment response and remission at the one-month follow-up after the second dose, defined as a drop of at least 50 percent in clinician-rated CAPS-5 severity to a score of 20 or lower. Symptoms also improved significantly during preparatory therapy, before any psilocybin was given, and those who improved more before dosing did better at one month. With no control group, the pilot cannot separate the drug from the therapy. Lead author Stacey Armstrong described the results as striking specifically because of the population studied, patients who had already failed conventional treatment and typically face elevated risk of dropout, long-term disability, and suicide.
Why the pairing matters more than either study alone
PIVOT targets depression, not PTSD, and uses a different sponsor and design than the Ohio State pilot. They are not the same study, and this piece is not claiming PIVOT’s outcome based on a different trial’s result. What the pairing does show is an institutional pattern. The VA is now involved in 20 active clinical trials focused on psychedelic therapies for mental health conditions, spanning multiple sponsors and multiple indications, and now including a trial the VA itself directly sponsors and controls. A federal health system moving from supporting psychedelic research broadly to running its own efficacy trial is a real posture shift. And it is happening at the same moment closely adjacent research in the same patient population is producing results its lead author calls striking, though from a 12-person uncontrolled pilot.
The caveat VA states plainly, and this desk should too
VA’s own announcement is explicit that this remains research, not a change in clinical policy.
“Clinical use of these therapies outside of research will only be considered by VA once FDA approval is granted. VA strongly discourages self-medicating or attempting to replace other mental health treatment options with psychedelics or any other unprescribed substance.”
— U.S. Department of Veterans Affairs, PIVOT trial announcement
That caveat is worth taking as seriously as the trial launch itself. Nothing about PIVOT or the Ohio State result changes what’s available to a veteran today, and VA is making that distinction explicit in its own messaging rather than leaving it implied.
Why this belongs next to the desk’s existing coverage
This desk has tracked the VA’s institutional posture on psychedelics closely this year, including the HHS-VA memorandum of understanding signed in July, built explicitly around preparing workforce and data infrastructure for a future approved product. It has also tracked the broader federal coordination that MOU represents. PIVOT is a concrete instance of the kind of veteran clinical research the MOU is meant to expand, and veteran-specific evidence like the Ohio State pilot’s is the sort the MOU, as this desk described it, directs the agencies to coordinate in ways that could inform future FDA regulatory decisions and coverage policy. Together, these are not three separate stories. They are the same institutional shift showing up in a policy document, a funded trial, and a published result, within a matter of weeks of each other.
What Neither Trial Proves Yet
The Ohio State pilot is open-label, uncontrolled, and treated twelve participants (thirteen enrolled), real limitations on how far its remission figure should be generalized. Its own authors describe it as a safety and feasibility study rather than a definitive efficacy trial. PIVOT itself is randomized and controlled, a meaningfully more rigorous design, but as of this writing it is only just launching, with results not expected for years. Neither trial should be read as evidence that psilocybin is close to becoming an approved or accessible treatment for veterans specifically, and VA’s own statement makes that explicit.
A Shift Bigger Than Either Data Point Alone
A federal health system this size sponsoring its own randomized controlled psilocybin trial, rather than only supporting research led by others, is an institutional marker. It arrives days after a smaller, veteran-specific study reported results strong enough to draw the word striking from its own lead investigator. Neither fact alone would be more than an incremental update to a story this desk has followed all year. Together, they describe an institution whose posture toward this drug class has moved further, and faster, than a single announcement suggests. VA’s own caution that none of this changes what’s actually available to a veteran today remains the most important sentence in its own press release.